Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Samuel A FuntMichael LattanziKarissa A WhitingHikmat A Al-AhmadieColleen QuinlanMin Yuen TeoChung-Han LeeDavid Henry AggenDanielle ZimmermanDeaglan Joseph McHughArlyn ApolloTrey D DurdinHong TruongJeffrey KamradtMaged KhalilBradley LashIrina OstrovnayaAsia S McCoyGrace HettichAshley M RegazziMarwah JihadNeha RatnaAbigail BoswellKaitlyn FranceseYuanquan YangEdmund FolefacHarry W HerrS Machele DonatEugene J PietzakEugene K ChaTimothy F DonahueAlvin C GohWilliam C HuangDean F BajorinGopakumar V IyerBernard H BochnerArjun V BalarAmir MortazaviJonathan E RosenbergPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Neoadjuvant GC plus A is a promising regimen for MIBC and warrants further study. Patients with < pT2N0 experienced improved relapse-free survival. The PD-L1 positivity rate was low compared with published data, which limits conclusions regarding PD-L1 as a predictive biomarker.